← Back to Screener
Hoth Therapeutics, Inc. Common Stock (HOTH)
Price$0.74
Favorite Metrics
Price vs S&P 500 (26W)-62.54%
Price vs S&P 500 (4W)-29.68%
Market Capitalization$13.96M
All Metrics
Book Value / Share (Quarterly)$0.40
P/TBV (Annual)0.94x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-0.65
Price vs S&P 500 (YTD)-30.40%
EPS (TTM)$-0.91
10-Day Avg Trading Volume13.44M
EPS Excl Extra (TTM)$-0.91
EPS (Annual)$-0.90
ROI (Annual)-202.73%
Cash / Share (Quarterly)$0.40
ROA (Last FY)-164.00%
EBITD / Share (TTM)$-0.89
ROE (5Y Avg)-155.54%
Cash Flow / Share (Annual)$-0.65
P/B Ratio2.27x
P/B Ratio (Quarterly)2.50x
Net Income / Employee (Annual)$-6
Net Interest Coverage (TTM)-114.51x
ROA (TTM)-126.88%
EPS Incl Extra (Annual)$-0.90
Current Ratio (Annual)4.72x
Quick Ratio (Quarterly)4.47x
3-Month Avg Trading Volume1.93M
52-Week Price Return-5.66%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$2.42
52-Week High$2.12
EPS Excl Extra (Annual)$-0.90
CapEx CAGR (5Y)12.03%
Tangible BV CAGR (5Y)34.02%
26-Week Price Return-53.80%
Quick Ratio (Annual)4.47x
13-Week Price Return-30.14%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)4.72x
Enterprise Value$7.716
Book Value / Share Growth (5Y)-45.95%
Revenue / Employee (Annual)$0
Cash / Share (Annual)$0.40
3-Month Return Std Dev110.42%
Net Income / Employee (TTM)$-6
ROE (Last FY)-202.73%
Net Interest Coverage (Annual)-61.73x
EPS Basic Excl Extra (Annual)$-0.90
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-0.91
ROI (TTM)-139.85%
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$3.93
Price vs S&P 500 (52W)-40.76%
Year-to-Date Return-26.26%
5-Day Price Return42.61%
EPS Normalized (Annual)$-0.90
ROA (5Y Avg)-130.20%
Month-to-Date Return-13.13%
EBITD / Share (Annual)$-0.90
ROI (5Y Avg)-155.54%
EPS Basic Excl Extra (TTM)$-0.91
P/TBV (Quarterly)0.46x
P/B Ratio (Annual)2.50x
Book Value / Share (Annual)$0.40
Price vs S&P 500 (13W)-33.01%
Beta0.48x
Revenue / Share (TTM)$0.00
ROE (TTM)-139.85%
52-Week Low$0.49
Analyst Recommendations
Jan 2026
Feb 2026
Mar 2026
Apr 2026
4.14
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(309)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
HOTHHoth Therapeutics, Inc. Common Stock | — | — | — | — | $0.74 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Hoth Therapeutics is a clinical-stage biopharmaceutical company developing targeted therapies across oncology, immunology, neurology, and dermatology. Its pipeline includes treatments for cancer treatment side effects (HT-001), mast cell cancers and anaphylaxis (HT-KIT), Alzheimer's disease (HT-ALZ), atopic dermatitis (BioLexa), asthma and allergies (HT-004), and obesity (HT-VA). The company focuses on areas with significant unmet medical needs.